Patricia Novo

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

Joshua D. Lee, Edward V. Nunes, Patricia Novo et al. · The Lancet · 2017 · 681 citations · Full text

Opioid Epidemic, Comparative Effectiveness, Substance Abuse +10

Cost-Effectiveness of Buprenorphine–Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse

Sean M. Murphy, Kathryn E. McCollister, Jared A. Leff et al. · Annals of Internal Medicine · 2018 · 67 citations · Full text

NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale

Joshua D. Lee, Edward V. Nunes, Patricia Novo et al. · Contemporary Clinical Trials · 2016 · 60 citations · Full text

Extended-release Naltrexone, Opioid Epidemic, Substance Abuse +15

Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial

Aimee Campbell, Celestina Barbosa‐Leiker, Mary A. Hatch‐Maillette et al. · American Journal on Addictions · 2018 · 60 citations

Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment

Edward V. Nunes, Jennifer Scodes, Martina Pavlicová et al. · American Journal of Psychiatry · 2021 · 34 citations · Full text